Results 181 to 190 of about 61,480 (319)

Acute Liver Failure With Transient Liver Steatosis Following Multiple Hits Postoperatively in a Patient With Limb‐Girdle Muscular Dystrophy: A Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Transient liver steatosis is rarely described. A fast development of liver steatosis leading to acute liver failure (ALF) is, to our knowledge, rarely observed. It is so far observed and published in acute fatty liver of pregnancy, and in a few cases of ALF. However, it is observed in elective surgery for pancreaticoduodenectomy and some cases
Anders Benjamin Kildal, Espen Molden, Elisabeth Myrseth, Didrik Kjønås, Gunnar Oltmanns, Rasmus Goll, Kim Erlend Mortensen, Geir Ivar Nedredal   +7 more
wiley   +1 more source

CYP3A4 activity in 3D PHHs.

Lukáš Lochman (21095097), Ellen Tanaka Kahiya (21095100), Bechara Saade (21095103), Tomáš Smutný (21095106), Jurjen Duintjer Tebbens (20550221), Petr Pávek (5847332), Veronika Bernhauerová (10112998)   +6 more
openalex   +1 more source

CYP3A4-V Polymorphism Detection by PCR-Restriction Fragment Length Polymorphism Analysis and Its Allelic Frequency among 199 Dutch Caucasians [PDF]

, 2000
Ron H. N. van Schaik, Saskia N. de Wildt, Nienke M van Iperen, André G. Uitterlinden, John N. van den Anker, Jan Lindemans   +5 more
openalex   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 375-380, February 2026.
A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered ...
Joseph Piscitelli, Micaela B. Reddy, Lance Wollenberg, Laurence Del Frari, Jason Gong, Kyle Matschke, Jason H. Williams   +6 more
wiley   +1 more source

Allelic variation in CYP3A4 and PLB1 drives feed efficiency and immunometabolic resilience in beef cattle. [PDF]

BMC Genomics
Morenikeji OB, Idowu M, Taiwo G, Gratz LM, Olabosoye B, King RE, Andrews ND, Saccoh F, Grytsay A, Marshall MC, Ogunade IM.   +10 more
europepmc   +1 more source

CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats [PDF]

, 2017
Ye Xu, Yifan Zhang, Xiaoyan Chen, Dafang Zhong   +3 more
openalex   +1 more source

Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters

Drug Metabolism And Disposition, 2016
Lydia M. M. Vermeer, Caleb D. Isringhausen, Brian W. Ogilvie, David B. Buckley   +3 more
semanticscholar   +1 more source

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 314-317, February 2026.
Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug–drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI‐related parameters have often been considered a limitation for predicting PBPK‐DDIs.
Kunal S. Taskar, Pradeep Sharma, Karen Rowland Yeo   +2 more
wiley   +1 more source

Potential Drug Interactions in Psychiatric Patients Undergoing Pangenotypic Therapy for Hepatitis C Virus Infection. [PDF]

Pharmaceuticals (Basel)
Dybowska D, Pawłowska M, Kozielewicz D.
europepmc   +1 more source